// App-Quantinova.ai

7519 : Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.

Researchers

Presenter

  • Loretta J. Nastoupil

Principal Investigators

  • Jason R. Westin

  • Nathan Hale Fowler

  • Michelle A. Fanale

  • Felipe Samaniego

  • Yasuhiro Oki

  • Chizobam Obi

  • Jing Jing Cao

  • Xiaoyun Cheng

  • Man Chun John Ma

  • Zhiqiang Wang

  • Fuliang Chu

  • Lei Feng

  • Shouhao Zhou

  • Richard Eric Davis

  • Sattva Swarup Neelapu

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Rituximab

Outcome

  • Unknown

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT02446457

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved